The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
A non-binary transfeminine person experienced significant hair regrowth after starting finasteride, minoxidil, microneedling, and hormone replacement therapy with estradiol. They encourage trans individuals concerned about hair loss to consider estrogen as it has greatly improved their hair condition.
A 21-year-old experienced erectile dysfunction after using finasteride and consuming multiple drugs, including MDMA, LSD, and weed. He plans to quit finasteride and weed, improve his habits, and consider alternative treatments like mesotherapy with dutasteride.
Users are concerned about inconsistencies in the packaging and form of a Minoxidil, finasteride, and Biotin blend from LockLab.co, with some receiving capsules and others tablets. Despite reassurances from customer service about changes due to maintenance, users remain skeptical about the product's authenticity and effectiveness.
L. reuteri, a probiotic, is being explored for its potential benefits in treating androgenic alopecia, possibly enhancing finasteride's effects and reducing inflammation. The user combines this with finasteride, oral minoxidil, and other supplements, noting some improvement in hair loss.
The conversation humorously discusses hair loss treatments, mentioning spironolactone and cyproterone acetate. It reflects a sense of frustration and satire about the effectiveness of these treatments.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
A user with androgenic alopecia seeks advice on making topical spironolactone from pills due to poor reactions to the oral form and its unavailability in their country. They are looking for guidance on preparing it themselves.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
The user is struggling with the high cost of RU58841 and is seeking cheaper bulk sources, considering options like Carolina Chemical. Other users discuss alternative treatments like finasteride, minoxidil, and dutasteride, with mixed experiences on effectiveness.
A 52-year-old male with Multiple Sclerosis is considering using Finasteride and Testosterone Replacement Therapy (TRT) for hair loss but is advised to lose weight first to avoid side effects. He is currently focusing on diet, weight loss, and using Rogaine and microneedling for hair treatment.
A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.
The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.
SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.
Using both finasteride and spironolactone together is more effective for hair loss in females, as they have different mechanisms and complement each other. It's important to avoid these medications during pregnancy and choose birth control with anti-androgenic activity.
Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.
A person in their early 30s is experiencing increased hair shedding after stopping birth control and reducing spironolactone, which they've been on for years. They are concerned about the hair loss, which is different from their usual hereditary pattern, and are seeking advice.
The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.
A 19-year-old is experiencing hair thinning despite using finasteride, RU58841, LLLT, saw palmetto, pumpkin seed oil, and a healthy lifestyle for 114 days. They are concerned about the lack of improvement and are hesitant to start minoxidil due to dependency concerns.
The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about a user experiencing hair shedding after using a brand of RU58841, questioning its effectiveness and safety. Concerns are raised about RU58841 being an abandoned research chemical and the use of heavy oils like castor and argan oil potentially affecting absorption.
A 23-year-old has been using finasteride, dutasteride, and spironolactone to combat hair loss and hormonal acne, with mixed results and concerns about side effects. The user is experimenting with spironolactone despite its potential risks, hoping for skin and body hair improvements.
The conversation discusses using estradiol and its derivatives for hair loss without causing feminization. Users mention alternatives like alfatradiol, topical 17b-Estradiol, and DIM (Diindolylmethane).
The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.
The conversation is about determining which type of Saw Palmetto, either Chamaerops humilis or Serenoa repens, is effective for inhibiting the 5 alpha reductase enzyme related to hair loss. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.
A new supplement for hair growth combines black rice, prickly pear, and saw palmetto, showing promising results in increasing hair density and reducing hair loss. The supplement is considered a drug-free alternative to traditional treatments like minoxidil and finasteride.
Mixing spironolactone with minoxidil for hair loss is questioned, but concerns are raised about spironolactone's side effects, especially for men. RU58841 is suggested as a better alternative for topical use.
The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
A user shared their baseline bloodwork results before starting Finasteride 1mg every other day, seeking comparison with others who have done similar tests. They are interested in any changes observed after beginning the treatment.